London, UK, 11 March 2021 – Pulmocide Ltd., which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, today announces the publication of two papers in key scientific […]
Presentations And Publications
London, UK, 2 March 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that company scientists gave 4 […]
02 March 2020
London, UK, 13 August 2019 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that in vitro data published […]
13 August 2019
Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of invasive fungal lung infections, announces the publication of data demonstrating the synergistic antifungal effect of combining topical administration […]
02 July 2019
A recent publication in Drug Discovery Today by pulmocide scientists provides an in depth review on current approaches to the discovery of new treatments which are administered by the inhaled […]
29 May 2018
Pulmocide is pleased to announce another PC945 publication in Antimicrobial Agents and Chemotherapy. The publication is available to download from the link below: AAC.ASM.ORG or the PDF can be downloaded […]
03 July 2017